<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4283">
  <stage>Registered</stage>
  <submitdate>14/01/2014</submitdate>
  <approvaldate>14/01/2014</approvaldate>
  <nctid>NCT02038036</nctid>
  <trial_identification>
    <studytitle>Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.</studytitle>
    <scientifictitle>Randomized, Open Label, Multicenter Phase IIIb Study Evaluating the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant (Response 2)</scientifictitle>
    <utrn />
    <trialacronym>RESPONSE-2</trialacronym>
    <secondaryid>CINC424B2401</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Polycythemia Vera</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Best Available Therapy
Treatment: drugs - ruxolitinib

Experimental: Ruxolitinib - 52 patients- at a starting dose of 10 mg bid. Dose may be adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid.

Active Comparator: Best Available Therapy - 52 patients - as selected by the investigator from: Hydroxyurea, IFN/PEG-IFN, popobroman, anagrelide, IMIDs, or observation


Treatment: drugs: Best Available Therapy
Best Available Therapy as selected by the investigator from the below: 1. Hydroxyurea 2. IFN/PEG-IFN 3. Pipobroman 4. Anagrelide 5. IMIDs 6. Observation only

Treatment: drugs: ruxolitinib
Supplied as tablets. Starting dose of 10 mg bid. Based on efficacy and safety parameters, dose may be increased or decreased. Maximum dose allowed is 25mg bid.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Efficacy of ruxolitinib to Best Available Therapy (BAT) as assessed by Hct control at Week 28 - Proportion of patients achieving Hct control at Week 28 as defined by: Hct &lt; 45% at Week 16 and maintained until Week 28, and No phlebotomy from Week 4 to Week 28, with no more than one phlebotomy occurring post randomization and prior to the Week 4 visit.</outcome>
      <timepoint>Week 28</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy of ruxolitinib to BAT as assessed by peripheral blood count remission at Week 28. - Proportion of patients achieving a peripheral blood count remission at Week 28 as defined by: Hct &lt; 45% at Week 16 and maintained until Week 28, and WBC &lt; 10 x10E9/L at Week 16 and maintained until Week 28, and Platelets = 400 x 10E9/L at Week 16 and maintained until Week 28, and No phlebotomy from Week 4 to Week 28, with no more than one phlebotomy occurring post randomization and prior to the Week 4 visit.</outcome>
      <timepoint>Week 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy of ruxolitinib to BAT as assessed by durable Hct control at Week 52 - Proportion of patients achieving a Hct control at Week 52 as defined by: Hct &lt; 45% at Week 16 and maintained until Week 52, and no phlebotomy from Week 4 to Week 28, with no more than one phlebotomy occurring post randomization and prior to the Week 4 visit, and, in the BAT arm, no change in the treatment regimen or crossover to the ruxolitinib arm.</outcome>
      <timepoint>Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy of ruxolitinib to BAT as assessed by durable peripheral blood count remission at Week 52. - Proportion of patients achieving a peripheral blood count remission at Week 52 as defined by: Hct &lt; 45% at Week 16 and maintained until Week 52, and WBC &lt; 10 x10E9/L at Week 16 and maintained until Week 52, and Platelets = 400 x 10E9/L at Week 16 and maintained until Week 52, and, no phlebotomy from Week 4 to Week 52, with no more than one phlebotomy occurring post randomization and prior to the Week 4 visit, and in the BAT arm, no change in the treatment regimen or crossover to the ruxolitinib arm.</outcome>
      <timepoint>Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in ECOG status - Change in ECOG status from baseline to Week 28</outcome>
      <timepoint>Week 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in spleen length - Change from Baseline in spleen length at each scheduled visit</outcome>
      <timepoint>Week 4, 8, 12, 16, 20, 24, 28, 40, 52/End of Treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy of ruxolitinib to BAT as assessed by partial remission based on the ELN and IWG-MRT criteria at Week 28 - Proportion of patients achieving a partial remission at Week 28, based on the ELN and IWG-MRT criteria, as defined by: MPN-SAF TSS score reduction of greater than or equal to 10 points from baseline to Week 16 and maintained until Week 28 (for patients with a baseline score of 20 or more), and Hct &lt; 45% at Week 16 and maintained until Week 28, and No phlebotomy from Week 4 to Week 28, with no more than one phlebotomy occurring post randomization and prior to the Week 4 visit, and WBC &lt; 10 x10E9/L at Week 16 and maintained until Week 28, and Platelets = 400 x 10E9/L at Week 16 and maintained until Week 28, and No palpable spleen at Week 16 and maintained until Week 28, and No hemorrhagic or thrombotic events, and No transformation into post-PV myelofibrosis, myelodysplastic syndrome, or acute leukemia</outcome>
      <timepoint>Week 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy of ruxolitinib to BAT as assessed by durable partial remission based on the ELN and IWG-MRT criteria at Week 52. - Proportion of patients who achieved partial remission at Week 52, based on the ELN and IWG-MRT criteria, as defined by: MPN-SAF TSS score reduction of greater than or equal to 10 points from baseline to Week 16 and maintained until Week 52 (for patients with a baseline score of 20 or more), and Hct &lt; 45% at Week 16 and maintained until Week 52, and No phlebotomy from Week 4 to Week 52, with no more than one phlebotomy occurring post randomization and prior to the Week 4 visit, and WBC &lt; 10 x10E9/L at Week 16 and maintained until Week 52, and Platelets = 400 x 10E9/L at Week 16 and maintained until Week 52, and No palpable spleen at Week 16 and maintained until Week 52, and No hemorrhagic or thrombotic events, and No transformation into post-PV myelofibrosis, myelodysplastic syndrome (IWG-MRT criteria) or acute leukemia (WHO criteria), and In the BAT arm, no change in the treatment regimen or crossover to the ruxolitinib arm.</outcome>
      <timepoint>Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy of BAT patients after they cross over to ruxolitinib - Among patients randomized to BAT who cross over to ruxolitinib, proportion of patients achieving Hct &lt; 45% at each visit after cross over</outcome>
      <timepoint>+4, +8, +12, +16, +20, +24 weeks after crossover</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in MPN-SAF TSS - Proportion of patients achieving at least a 50% reduction from baseline in MPN-SAF TSS score at each visit where it is measured.</outcome>
      <timepoint>Week 4, 8, 16, 28, 40, 52/End of Treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Resolution of disease related symptoms in MPN-SAF TSS at Week 28. - Proportion of patients achieving a resolution of disease related symptoms in MPN-SAF TSS at Week 28 defined as:  MPN-SAF TSS score reduction of greater than or equal to 10 points from baseline to Week 16 and maintained until Week 28 (for patients with a baseline score of 20 or more).</outcome>
      <timepoint>Week 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in patient reported outcomes - Change in MPN-SAF TSS from baseline to each visit where measured.
PSIS at each visit where measured.
Change in EQ-5D-5L score from baseline to each visit where measured.
Change in WPAI from baseline to each visit where measured.
PGIC at each visit where measured.</outcome>
      <timepoint>Week 4, 8, 16, 28, 40, 52/End of Treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety of ruxolitinib and Best Available Therapy - Safety will be assessed by monitoring the frequency, duration and severity of Adverse Events, and evaluating changes in vital signs, electrocardiograms (ECGs), serum chemistry, hematology and urinalysis results.</outcome>
      <timepoint>Week 28, 52/EoT</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety of BAT patients after they crossover - Safety will be assessed by monitoring the frequency, duration and severity of Adverse Events, and evaluating changes in vital signs, electrocardiograms (ECGs), serum chemistry, hematology and urinalysis results.</outcome>
      <timepoint>+52/EoT</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Confirmed diagnosis of PV according to the 2008 World Health Organization criteria,
             Non-palpable spleen, Phlebotomy dependent, Resistant to or intolerant of hydroxyurea,
             ECOG performance status of 0, 1 or 2.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Inadequate liver or renal function, Significant bacterial, fungal, parasitic, or viral
             infection requiring treatment, Active malignancy within the past 5 years, excluding
             specific skin cancers, Previously received treatment with a JAK inhibitor, Being
             treated with any investigational agent, Women who are pregnant or nursing. Other
             inclusion/exclusion criteria apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>25/03/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>149</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>20/04/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>Novartis Investigative Site - Herston</hospital>
    <postcode>4029 - Herston</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerpen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brugge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bayonne cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Brest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Strasbourg cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse Cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Baden-Württemberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Augsburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Jena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Magdeburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Minden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ulm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Kaposvar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Andhra Pradesh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Maharashtra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Tamil Nadu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>West Bengal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Nahariya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Netanya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>BO</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>FI</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lazio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>MI</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>PV</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>TO</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>VA</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Korea</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Andalucia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Castilla y Leon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Catalunya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Comunidad Valenciana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Galicia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Las Palmas de G.C</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Navarra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Talas / Kayseri</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial will compare the efficacy and safety of ruxolitinib to Best Available Therapy
      (BAT) in patients with polycythemia vera (PV) who are hyroxyurea (HU) resistant or intolerant
      and do not have a palpable spleen.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02038036</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>